StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) shareholders

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
75.3%
147M of 195M shares
Institutional holders
131
47 new, 18 sold out
Net institutional buying
53M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $29.29K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Rajeev Shah
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
19,549,2719.90%13G (passive) amendmentJun 30, 2026
Sirenia Capital Management LP
Joint filing with Alex Silverstein (9.90%)
18,031,3339.90%13G (passive)Mar 31, 2026
Michael Cho
Joint filing with Affinity Asset Advisors, LLC (9.10%)
15,635,4849.10%13G (passive) amendmentMar 31, 2026
Affinity Asset Advisors, LLC
Joint filing with Michael Cho (7.90%)
15,143,7287.90%13G (passive) amendmentJun 30, 2026
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more
13,259,7359.90%13G (passive)Dec 11, 2025
Robin C. John
Joint filing with Eventide Asset Management, LLC (7.30%), Finny Kuruvilla, M.D., Ph. D. (7.30%)
12,773,5777.30%13G (passive)Mar 31, 2026
Affinity Healthcare Fund, LP
Joint filing with Affinity Asset Advisors, LLC (9.00%)
12,149,1669.00%13G (passive)Dec 11, 2025
Eventide Asset Management, LLC
Joint filing with Finny Kuruvilla, M.D., Ph. D. (6.30%), Robin C. John (6.30%)
11,812,2416.30%13G (passive) amendmentJun 30, 2026
BlackRock, Inc.10,822,6725.80%13G (passive)Jun 30, 2026
ADAR1 Capital Management, LLC
Joint filing with Daniel Schneeberger (5.10%)
9,559,9795.10%13G (passive) amendmentJun 30, 2026
Takeda Pharmaceutical Company Limited
Joint filing with Takeda Pharmaceutical U.S.A., Inc. (9.80%)
8,781,99612.30%13G (passive) amendmentDec 8, 2025
Voting Shares Irrevocable Trust
Joint filing with Federated Hermes, Inc. (5.94%), Thomas R. Donahue (5.94%) and 2 more
7,737,1665.94%13G (passive)Dec 31, 2025
Janus Henderson Group PLC7,114,1149.99%13G (passive)Nov 28, 2025
Dmitry Balyasny
Joint filing with Balyasny Asset Management L.P. (5.33%), Bam Gp LLC (5.33%) and 2 more
7,029,2235.33%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of OVIDValueChange% of portfolio
Jupiter Topco LLC20,741,23410.62%$55.90MNew0.02%
Eventide Asset Management, LLC11,812,2416.05%$31.77M+1,895,3300.42%
BlackRock, Inc.10,823,4805.54%$29.12M+9,290,1970.00%
Ra Capital Management, L.P.10,500,9685.38%$28.25M−213,0320.25%
Affinity Asset Advisors, LLC10,144,5625.19%$27.29M−491,7561.23%
State Street Corp7,900,7654.05%$21.25M+7,380,4820.00%
Vanguard Capital Management LLC7,760,1143.97%$20.87M+2,501,8680.00%
ADAR1 Capital Management, LLC7,417,4793.80%$19.95M+2,873,3660.91%
Balyasny Asset Management L.P.6,719,0763.44%$18.07M+1,186,0030.02%
Adage Capital Partners Gp, L.L.C.6,163,7813.16%$16.58M–0.02%
Federated Hermes, Inc.5,951,6663.05%$16.01M+2,380,6660.02%
Braidwell LP5,919,4643.03%$15.92MNew0.59%
Geode Capital Management, LLC4,072,6532.09%$10.96M+2,754,5620.00%
Silverarc Capital Management, LLC3,101,1291.59%$8.34M+2,101,1290.87%
Stempoint Capital LP2,417,2831.24%$6.50MNew1.12%
Ikarian Capital, LLC2,269,7041.16%$6.11M−625,0000.66%
Point72 Asset Management, L.P.1,945,7271.00%$5.23M+625,1170.01%
Sphera Funds Management Ltd.1,353,0000.69%$3.64M−269,8280.47%
Northern Trust Corp1,246,1390.64%$3.35M+991,3350.00%
Vanguard Fiduciary Trust Co1,140,7530.58%$3.07M+447,4970.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026131147M75.3%47 / 3327 / 1871M19M
Q1 2026103105M53.8%30 / 3320 / 1053M7M
Q4 20258462M31.6%20 / 2524 / 1342M8M
Q3 20258136M18.5%25 / 1823 / 1411M10M
Q2 20257136M18.4%17 / 1622 / 274M15M
Q1 20258246M23.8%10 / 2028 / 95M6M
Q4 20248248M24.4%14 / 2421 / 73M4M
Q3 20247548M24.5%10 / 3115 / 89M4M
Q2 20247447M24.3%14 / 2225 / 215M9M
Q1 20248152M26.6%12 / 2922 / 82M4M
Q4 20237753M27.4%17 / 2517 / 312M0M
Q3 20236442M21.7%5 / 1820 / 92M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

69 funds held OVID in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of OVIDValue% of fundAs of
Vanguard Total Stock Market Index Fund5,653,2162.89%$15.21M0.00%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF4,920,5172.52%$13.24M0.12%Jun 30, 2026
iShares Russell 2000 ETF3,885,2841.99%$10.45M0.01%Jun 30, 2026
Federated Hermes Kaufmann Small Cap Fund2,380,6661.22%$5.29M0.19%Jul 31, 2026
Vanguard Extended Market Index Fund1,952,6221.00%$5.25M0.01%Jun 30, 2026
Eventide Healthcare & Life Sciences Fund1,934,2570.99%$5.20M0.29%Jun 30, 2026
Fidelity Small Cap Index Fund1,676,7230.86%$3.72M0.01%Jul 31, 2026
iShares Russell 2000 Value ETF1,214,1670.62%$3.27M0.02%Jun 30, 2026
Nuveen Equity Index Fund646,5520.33%$1.44M0.00%Jul 31, 2026
Fidelity Extended Market Index Fund613,4580.31%$1.67M0.00%May 31, 2026
iShares Micro-Cap ETF514,1600.26%$1.38M0.09%Jun 30, 2026
Schwab Small-Cap Index Fund372,0240.19%$825.89K0.01%Jul 31, 2026
Master Small Cap Index Series286,2340.15%$769.97K0.01%Jun 30, 2026
Fidelity Total Market Index Fund215,7140.11%$588.90K0.00%May 31, 2026
Nuveen Small Cap Blend Index Fund203,8120.10%$452.46K0.01%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jeremy M. LevinExecutive Chairman, Director3,770,5091.93%Mar 25, 2026
Margaret A. AlexanderPresident and CEO, Director61,7500.03%Mar 2, 2026
Charles Ross CarterChief Financial Officer44,3750.02%Jul 8, 2026
Jeffrey A. RonaCBFO156,3130.08%Mar 2, 2026
Anna GrekaDirector––Jun 17, 2026
Bart FriedmanDirector8,7890.00%Apr 9, 2026
Stelios PapadopoulosDirector217,5780.11%Apr 9, 2026
Kevin Joseph FitzgeraldDirector17,5780.01%Apr 9, 2026
Karen BernsteinDirector20,0000.01%Mar 2, 2026
Barbara Gayle DuncanDirector––Mar 2, 2026
Pharmaceutical Co Ltd Takeda10% owner7,531,9963.86%Dec 9, 2025
Takeda Pharmaceuticals U.S.A., Inc.10% owner8,781,9964.50%Dec 9, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Charles Ross Carter
Chief Financial Officer
Jul 6, 2026Award+50,000––94,375
Kevin Joseph Fitzgerald
Director
Apr 7, 2026Award+17,578$2.56$45.00K17,578
Stelios Papadopoulos
Director
Apr 7, 2026Award+17,578$2.56$45.00K217,578
Bart Friedman
Director
Apr 7, 2026Award+8,789$2.56$22.50K8,789
Jeremy M. Levin
Executive Chairman, Director
Mar 23, 2026Option exercise+47,333$1.40$66.27K3,735,048
Jeffrey A. Rona
CBFO
Feb 26, 2026Award+68,125––156,313
Margaret A. Alexander
President and CEO, Director
Feb 23, 2026Sale−11,656$1.45$16.90K61,750
Jeffrey A. Rona
CBFO
Feb 23, 2026Sale−8,541$1.45$12.38K88,188
Jeremy M. Levin
CEO, Director
Dec 15, 2025Conversion+71,000––3,687,715
Takeda Pharmaceuticals U.S.A., Inc.
10% owner
Dec 8, 2025Conversion+1,250,000––7,000,000
Jeffrey A. Rona
CBFO
Feb 26, 2025Sale−3,902$0.56$2.19K67,973
Margaret A. Alexander
President and COO
Feb 26, 2025Sale−5,279$0.56$2.96K73,406
Jeffrey A. Rona
CBFO
Feb 20, 2025Award+43,750––71,875
Margaret A. Alexander
President and COO
Feb 20, 2025Award+43,750––78,685
Margaret A. Alexander
President and COO
Jan 27, 2025Buy+6,810$0.73$4.97K34,935
Jeremy M. Levin
CEO, Director
Mar 18, 2024Buy+18,248$2.76$50.36K3,616,715
Jason Tardio
Chief Operating Officer
Feb 22, 2024Award+28,125––28,125
Jeffrey A. Rona
CBFO
Feb 22, 2024Award+28,125––28,125
Thomas Michael Perone
General Counsel, Secretary
Feb 22, 2024Award+28,125––28,125
Jeremy M. Levin
CEO, Director
Dec 4, 2023Gift−573,275––4,171,742
Jeremy M. Levin
CEO, Director
Dec 4, 2023Gift−573,275––3,598,467
Jason Tardio
Chief Operating Officer
Sep 12, 2022Sale−17,344$2.15$37.29K0
Pharmaceutical Co Ltd Takeda
10% owner
Jul 1, 2022Other+5,750,000––5,750,000
Pharmaceutical Co Ltd Takeda
10% owner
Jul 1, 2022Other−5,750,000––0
Amit Rakhit
President and CMO
Jul 14, 2021Sale−34,017$3.71$126.20K726,823
Amit Rakhit
President and CMO
Jul 14, 2021Option exercise+34,017$1.89$64.29K760,840
Jeremy M. Levin
CEO, Director, 10% owner
Aug 28, 2020Buy+8,488$5.84$49.57K5,792,530
Pharmaceutical Co Ltd Takeda
10% owner
Oct 8, 2019Buy+2,000,000$2.50$5.00M5,750,000
Jeremy M. Levin
CEO, Director, 10% owner
Oct 8, 2019Buy+60,000$2.50$150.00K4,736,529
Jeremy M. Levin
CEO, Director
Sep 20, 2019Gift−465,116––0
Karen Bernstein
Director
Feb 26, 2019Buy+10,000$2.02$20.20K20,000
Jeremy M. Levin
CEO, Director, 10% owner
Feb 22, 2019Buy+75,000$2.00$150.00K4,676,529
Karen Bernstein
Director
Aug 14, 2018Buy+10,000$6.23$62.30K10,000
Douglas E. Williams
Director
Aug 14, 2018Buy+5,000$6.49$32.45K5,000
Jeremy M. Levin
CEO, Director, 10% owner
Aug 25, 2017Buy+15,334$7.15$109.64K4,601,529
Jeremy M. Levin
CEO, Director, 10% owner
May 10, 2017Conversion+35,461––35,461
Jeremy M. Levin
CEO, Director, 10% owner
May 10, 2017Conversion+400,150––4,586,195
Matthew During
President and CSO, Director, 10% owner
May 10, 2017Conversion+28,245––4,307,314

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
10.75%
18M shares short
Days to cover
8.2
At 2M shares a day
Change since last report
+0.4%
From 18M shares
Short volume, 20 days
49.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ovid Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 476,759 shares on Sep 21, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jeffrey A. Rona
Affiliated Stockholder
Aug 24, 2026325,000$910.00KAug 24, 2026Stock Option Exercise
Jeffrey A. Rona
Affiliated Stockholder
Aug 14, 2026150,000$420.00KAug 14, 2026ESPP Purchase

See a number that looks wrong?